Key points
- Revenue up 3% to $114.5m, EBITDA up 19% to $10.9m
- Positive operating cash flow before leases of $8.3m
- Manufacturing capacity expanded by over 40% across 2 years
- New product Virtus designed for OSA and sleep bruxism
- Targeting high single-digit revenue growth in FY27
Full summary
Somnomed Ltd, the global leader in oral appliance therapy, reported strong financial results for FY26. Revenue increased by 3% to $114.5m, with EBITDA rising 19% to $10.9m, reflecting higher revenue, improved gross margin, and disciplined cost management. Operating cash flow before leases was positive at $8.3m. Manufacturing capacity expanded by over 40% across two years, and production times improved by over 50%. The new product Virtus, designed for patients with OSA and sleep bruxism, is undergoing a controlled global release. The company is targeting high single-digit revenue growth in FY27, with a focus on product innovation and market expansion.
Guidance
Targeting high single-digit revenue growth in FY27, maintaining EBITDA1 margins consistent with FY26
Outlook
Somnomed is targeting high single-digit revenue growth in FY27, with a focus on successful global adoption of Virtus and stable EBITDA1 margins.